American clinical stage biopharmaceutical company headquartered at Waltham in Massachusetts with an office at Cincinnati in Ohio, founded in 2018 and listed on Nasdaq until AstraZeneca acquired it in 2023. Developed baxdrostat, an aldosterone synthase inhibitor, for treatment resistant hypertension, chronic kidney disease and primary aldosteronism, taking it through phase two trials before the acquisition, and the programme continues within AstraZeneca's cardiovascular, renal and metabolic portfolio.
Chưa có bình luận nào.
Để lại đánh giá & nhận xét